Loading...
XJPX6869
Market cap11bUSD
Dec 23, Last price  
2,932.00JPY
1D
0.57%
1Q
4.14%
Jan 2017
29.93%
Name

Sysmex Corp

Chart & Performance

D1W1MN
XJPX:6869 chart
P/E
36.83
P/S
3.96
EPS
79.61
Div Yield, %
0.96%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
9.47%
Revenues
461.51b
+12.43%
76,934,000,00087,887,000,000101,041,000,000110,724,000,000111,842,000,000116,174,000,000124,694,000,000134,743,000,000145,577,000,000184,538,000,000221,376,000,000253,157,000,000249,899,000,000281,935,000,000293,506,000,000301,980,000,000305,073,000,000363,780,000,000410,502,000,000461,510,000,000
Net income
49.64b
+8.42%
5,731,000,0007,422,000,0009,008,000,0009,131,000,0008,013,000,0009,764,000,00011,411,000,00012,007,000,00014,165,000,00020,573,000,00026,638,000,00036,233,000,00040,635,000,00039,221,000,00041,224,000,00034,882,000,00031,904,000,00044,092,000,00045,784,000,00049,639,000,000
CFO
63.91b
-7.16%
6,691,000,0008,275,000,00010,085,000,00011,634,000,00013,193,000,00021,229,000,00018,135,000,00017,058,000,00025,806,000,00036,563,000,00038,640,000,00039,567,000,00032,832,000,00052,240,000,00044,743,000,00053,182,000,00058,813,000,00058,739,000,00068,835,000,00063,905,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 07, 2025

Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
URL
https://www.sysmex.co.jp/
IPO date
Nov 15, 1995
Employees
9,500
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
461,510,000
12.43%
410,502,000
12.84%
363,780,000
19.24%
Cost of revenue
384,213,000
337,850,000
294,214,000
Unusual Expense (Income)
NOPBT
77,297,000
72,652,000
69,566,000
NOPBT Margin
16.75%
17.70%
19.12%
Operating Taxes
24,826,000
22,988,000
20,274,000
Tax Rate
32.12%
31.64%
29.14%
NOPAT
52,471,000
49,664,000
49,292,000
Net income
49,639,000
8.42%
45,784,000
3.84%
44,092,000
38.20%
Dividends
(17,579,000)
(16,528,000)
(15,258,000)
Dividend yield
1.05%
0.91%
0.82%
Proceeds from repurchase of equity
(11,298,000)
267,000
1,384,000
BB yield
0.68%
-0.01%
-0.07%
Debt
Debt current
8,659,000
7,149,000
6,439,000
Long-term debt
73,419,000
38,033,000
38,119,000
Deferred revenue
3,000
2,662,000
1,579,000
Other long-term liabilities
13,342,000
7,062,000
8,540,000
Net debt
(30,470,000)
(57,372,000)
(61,988,000)
Cash flow
Cash from operating activities
63,905,000
68,835,000
58,739,000
CAPEX
(25,610,000)
(42,505,000)
(32,034,000)
Cash from investing activities
(54,970,000)
(51,751,000)
(35,052,000)
Cash from financing activities
(9,013,000)
(24,234,000)
(20,542,000)
FCF
(10,816,000)
29,079,000
21,845,000
Balance
Cash
76,607,000
70,335,000
75,250,000
Long term investments
35,941,000
32,219,000
31,296,000
Excess cash
89,472,500
82,028,900
88,357,000
Stockholders' equity
424,379,000
736,829,000
668,875,000
Invested Capital
412,102,500
323,289,100
280,281,000
ROIC
14.27%
16.46%
18.85%
ROCE
15.17%
17.61%
18.54%
EV
Common stock shares outstanding
626,439
627,960
628,422
Price
2,661.50
-7.62%
2,881.00
-3.14%
2,974.33
-25.17%
Market cap
1,667,266,512
-7.84%
1,809,152,760
-3.21%
1,869,134,407
-25.10%
EV
1,637,647,512
2,121,211,760
2,147,890,407
EBITDA
113,185,000
104,459,000
96,997,000
EV/EBITDA
14.47
20.31
22.14
Interest
2,386,000
1,566,000
909,000
Interest/NOPBT
3.09%
2.16%
1.31%